Events & Presentations Upcoming Events No upcoming events at this time Past Events SVB Securities Virtual Global Biopharma Conference 2023 Feb 16, 2023 at 2:20 PM EST Click here for webcast Investor Presentations ARS Pharmaceuticals - Corporate Presentation ARS Pharmaceuticals - Corporate Presentation 5.9 MB Scientific Presentations AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB ACAAI 2022 Poster 238 Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB ACAAI 2022 Poster 236 Pharmacokinetics and Pharmacodynamics of ARS-1 (neffy® Nasal Spray) and Manual Intramuscular Injection in Subjects With/Without Allergic Rhinitis 1.5 MB AAAAI 2022 Poster 007 Self-Administration of Intranasal Epinephrine (neffy ) Using the Aptar Unit Dose System Compared to EpiPen and Symjepi 637.1 KB ACAAI 2022 Poster 006 Time Before Use of Epinephrine Injectable Devices and Triggers Driving Use: A Patient/Caregiver Survey 1.3 MB AAAAI 2020 Poster 022 Learning from Epinephrine Treatment Characteristics Among Patients with Severe Allergic Reactions 787.7 KB Pagination Current page 1 Page 2 Next page next › Last page last »
Investor Presentations ARS Pharmaceuticals - Corporate Presentation ARS Pharmaceuticals - Corporate Presentation 5.9 MB Scientific Presentations AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB ACAAI 2022 Poster 238 Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB ACAAI 2022 Poster 236 Pharmacokinetics and Pharmacodynamics of ARS-1 (neffy® Nasal Spray) and Manual Intramuscular Injection in Subjects With/Without Allergic Rhinitis 1.5 MB AAAAI 2022 Poster 007 Self-Administration of Intranasal Epinephrine (neffy ) Using the Aptar Unit Dose System Compared to EpiPen and Symjepi 637.1 KB ACAAI 2022 Poster 006 Time Before Use of Epinephrine Injectable Devices and Triggers Driving Use: A Patient/Caregiver Survey 1.3 MB AAAAI 2020 Poster 022 Learning from Epinephrine Treatment Characteristics Among Patients with Severe Allergic Reactions 787.7 KB Pagination Current page 1 Page 2 Next page next › Last page last »
Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB
Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB
ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB
Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB
Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB
Pharmacokinetics and Pharmacodynamics of ARS-1 (neffy® Nasal Spray) and Manual Intramuscular Injection in Subjects With/Without Allergic Rhinitis 1.5 MB
Self-Administration of Intranasal Epinephrine (neffy ) Using the Aptar Unit Dose System Compared to EpiPen and Symjepi 637.1 KB
Time Before Use of Epinephrine Injectable Devices and Triggers Driving Use: A Patient/Caregiver Survey 1.3 MB
Learning from Epinephrine Treatment Characteristics Among Patients with Severe Allergic Reactions 787.7 KB
